Melanoma-inhibitory activity protein concentrations in the blood of melanoma patients treated with immunotherapy

Dreau, D. and Bosserhoff, Anja-Katrin and White, R. L. and Buettner, R. and Holder, W. D. (1999) Melanoma-inhibitory activity protein concentrations in the blood of melanoma patients treated with immunotherapy. ONCOLOGY RESEARCH, 11 (1). pp. 55-61. ISSN 0965-0407,

Full text not available from this repository. (Request a copy)

Abstract

Melanoma inhibitory activity protein (MIA) has been detected in patients with advanced melanoma. The present study measured the variations in blood concentrations of MIA in 84 patients with AJCC stage II to IV melanoma by ELISA. Patients treated with repeated injections of a polyvalent melanoma vaccine (PMV), interferon-alpha-2b (IFN-alpha 2b), or interleukin-2 (IL-2) were followed during treatment duration. Before treatment, patients treated with PMV or IFN-alpha 2b had comparable low MIA concentrations, whereas most IL-2-treated patients had higher MIA levels. At the end of treatment, MIA concentrations were higher in patients with progressive disease (PD) than in patients with no clinical evidence of melanoma (NPD) for PMV, IFN-alpha 2b, or IL-2 therapy (3.7 +/- 0.2 vs. 11.5 +/- 5.4 ng/ml, 3.8 +/- 0.2 vs. 8.3 +/- 1.7 ng/ml, and 2.3 +/- 0.7 vs. 20.2 +/- 7.4 ng/ml, respectively, P < 0.05). In constrast to stable MIA concentrations measured in NPD patients, significant increase in MIA levels were observed in PD patients over time regardless of treatment (P < 0.05). In 20 of the 27 patients who had melanoma recurrence or progression, MIA concentrations were above 4.5 ng/ml. Finally, in these 20 patients, MIA concentrations above 4.5 ng/ml were observed prior to clinical evidence of progression (P < 0.01).

Item Type: Article
Uncontrolled Keywords: PUTATIVE TUMOR-MARKERS; MALIGNANT-MELANOMA; METASTATIC MELANOMA; CUTANEOUS MELANOMA; 1ST RECURRENCE; S-100 PROTEIN; MESSENGER-RNA; TYROSINASE; VACCINE; EXPRESSION; blood; ELISA; IFN-alpha 2b; IL-2; immunotherapy; marker; melanoma; melanoma-inhibitory activity protein (MIA); threshold; vaccine
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Dermatologie und Venerologie
Medicine > Lehrstuhl für Pathologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 05 Dec 2022 08:16
Last Modified: 05 Dec 2022 08:16
URI: https://pred.uni-regensburg.de/id/eprint/48711

Actions (login required)

View Item View Item